Sepsis-associated encephalopathy and septic encephalitis: an update
ReviewHumans
- Design
- Review
- Subjects
- Not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- What causes sepsis-associated encephalopathy and septic encephalitis, how it is diagnosed, and how it is treated: a 2016 to 2020 literature review, including where palmitoylethanolamide fits among candidate treatments.
What the authors reported
The authors describe delirium as the main sign, inflammation and blood-brain barrier changes as causes, and antibiotics as the backbone of treatment. In their expert opinion they list palmitoylethanolamide among licensed drugs or supplements that might be effective, alongside statins, L-DOPA/benserazide, beta-hydroxybutyrate and tetracyclines. No PEA trial data are given.
Limits of this study
A narrative review; the mention of palmitoylethanolamide is an opinion, not a result. Funding and conflicts not stated in the abstract.
Source
PubMed 32808580 · doi:10.1080/14787210.2020.1812384
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.